Skip to main content
GANX
NASDAQ Life Sciences

Gain Therapeutics Reports 12-Month Phase 1b Data Showing Motor Score Stabilization in Parkinson's

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.753
Mkt Cap
$75.503M
52W Low
$1.53
52W High
$4.34
52W Position info
15% above low
Off High info
60% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

GANX is trading near its 52-week low of $1.53 (15% above the low).

Summary

Gain Therapeutics announced 12-month Phase 1b open-label extension data showing stabilization of motor symptoms in Parkinson's patients treated with rexaceract, with plans to initiate a Phase 2 trial in Q1 2027.

Updates

  1. · GlobeNewswire — Poster presented at MDS Congress; 12 of 13 evaluable patients completed 12-month dosing by Aug 31, 2026, with one to complete in November 2026.


Key Events · Product Development and Regulatory · GANX

  • 12-Month Motor Score Stabilization

    MDS-UPDRS motor scores remained stable over 360 days of dosing in 12 evaluable patients, with no clinically meaningful progression on Parts II and III — a threshold generally accepted as ~6 points per year in early PD.

  • Phase 2 Initiation Planned for Q1 2027

    Company expects to submit a new Phase 2 study protocol to the FDA in the coming weeks and initiate the Phase 2 clinical trial of rexaceract in Parkinson's disease in the first quarter of 2027.

  • Biomarker Data Supports Mechanism

    Participants with high baseline CSF GluSph levels showed a large decrease toward healthy levels after 90 days of treatment, suggesting increased GCase activity in the brain — consistent with rexaceract's proposed mechanism.

  • Favorable Long-Term Safety Profile

    No new safety signals observed over 12 months; lower incidence of treatment-emergent adverse events in the nine-month extension (Part 2) compared with the initial three-month period (Part 1).


Analysis · GANX · Life Sciences

The 12-month open-label extension data for rexaceract shows MDS-UPDRS motor scores remained stable over 360 days of dosing, with no clinically meaningful progression in 12 evaluable patients. This is the first long-term efficacy signal for the company's lead asset and supports its disease-modifying hypothesis in Parkinson's disease. The company also confirmed plans to submit a Phase 2 protocol to the FDA in the coming weeks and initiate the trial in Q1 2027, providing a concrete near-term development milestone. Against a backdrop of a going-concern warning and only $13.1M in cash as of Q2 2026, positive clinical data is critical for attracting partnership or financing interest to fund the next phase.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GANX was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.5M. The 52-week trading range was $1.53 to $4.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GANX - Latest Insights

GANX
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $1.01 info
Change: -$0.0726 (-7%) info
Market Cap: $46.306M info
GANX
Oct 01, 2026, 9:28 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.01 info
Change: -$0.7326 (-42%) info
Market Cap: $46.306M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.01 info
Change: -$0.9952 (-50%) info
Market Cap: $46.306M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.01 info
Change: -$1.05 (-51%) info
Market Cap: $46.306M info
GANX
Jul 16, 2026, 7:53 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.01 info
Change: -$0.6726 (-40%) info
Market Cap: $46.306M info